Molecular Analysis of Diabetic Kidney Disease Biopsies

Launched by UNITY HEALTH TORONTO · Jul 21, 2019

Keywords

ClinConnect Summary

This clinical trial, titled "Molecular Analysis of Diabetic Kidney Disease Biopsies," is focused on understanding diabetic kidney disease, which affects people with diabetes. Researchers are looking to study kidney tissue samples from patients who have diabetic kidney disease to find new molecules that might help explain why this disease progresses in some individuals and not in others. By analyzing these samples using a method called RNA sequencing, they aim to uncover changes in genes that are linked to kidney health and disease.

To participate in this study, individuals need to have a history of type 1 or type 2 diabetes and must have a kidney biopsy sample that shows signs of diabetic kidney disease. Healthy individuals may also be included if they have a kidney biopsy that shows no signs of disease. Participants can expect to contribute to important research that could lead to better understanding and treatment of diabetic kidney disease. The trial is currently recruiting participants, and they are looking for individuals aged 65 and older.

Gender

ALL

Eligibility criteria

• Inclusion Criteria (diabetic kidney disease cases):
• • history of type 1 or type 2 diabetes
• • at least 1 archived native kidney biopsy that demonstrates either pure diabetic kidney disease or features of non-specific vascular disease, including glomerulosclerosis, non-inflammatory vascular disease,
• • sufficient remaining archived kidney biopsy tissue for RNA sequencing (100 um thick tissue section) and histologic analysis (PAS and Masson Trichrome staining)
• Exclusion Criteria (diabetic kidney disease cases):
• • less than 3 eGFR values post-biopsy
• • latest recorded eGFR values less than 6 months post-biopsy
• Inclusion Criteria (healthy controls):
• • - at least 1 native kidney disease biopsy with no diagnostic abnormality